ESMO 2024: Optimising the personalisation of prostate cancer treatment
Prof Harrington talks to ecancertv at ASCO 2014 about a phase III study of adjuvant postoperative lapatinib with concurrent chemotherapy and radiation therapy in high-risk patients with squamous cell carcinoma of the head and neck.
ecancer's filming at ASCO has been kindly supported by Amgen through the ECMS Foundation. ecancer is editorially independent and there is no influence over content.
ESMO 2024: Optimising the personalisation of prostate cancer treatment
ASCO 2024: Lung cancer highlights
ELCC 2024: Latest in EGFR mutant lung cancer; exon 20 mutation focus
Multiple myeloma in a resource constrained setting
First-line NALIRIFOX shows improvement in OS and PFS in metastatic pancreatic cancer
Management of prostate cancer in Africa: Looking to the future
The current status of multiple myeloma diagnosis and treatment
Choosing Wisely in radiology Tanzania
TARGeted IORT INTRABEAM is a useful treatment option for early stage breast cancer